PATISIRAN (Onpattro®)
Clinical Indication
Hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy
Comments
Not yet reviewed
Date of classification
January 2020
Grey
Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.
- New medicines, devices, appliances.
- New indication of existing medicine.
- New NICE TA which has not been reviewed.
- Not been requested for review by either TAS/LPT MMC.